Literature DB >> 25809703

Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis.

Huojun Zhang1, Wei Xing, Qinqin Kang, Chao Chen, Linhui Wang, Jianping Lu.   

Abstract

An early diagnosis of urinary bladder cancer is crucial for early treatment and management. The objective of this systematic review was to assess the overall diagnostic accuracy of 18 F FDG-PET and PET/CT in urinary bladder cancer with meta-analysis. The PubMed and CNKI databases were searched for the eligible studies published up to June 01, 2014. The sensitivity, specificity, and other measures of accuracy of 18 F FDG-PET and PET/CT in the diagnosis of urinary bladder cancer were pooled along with 95 % confidence intervals (CI). Summary receiver operating characteristic (ROC) curves were used to summarize overall test performance. Ten studies met our inclusion criteria. The summary estimates for 18 F FDG-PET and PET/CT in the diagnosis of urinary bladder cancer in meta-analysis were as follows: a pooled sensitivity, 0.82 (95 % confidence interval [CI], 0.75 to 0.88); a pooled specificity, 0.92 (95 % CI, 0.87 to 0.95); positive likelihood ratio, 6.80 (95 % CI, 4.31 to 10.74); negative likelihood ratio, 0.27 (95 % CI, 0.19 to 0.36); and diagnostic odds ratio, 25.18 (95 % CI, 17.58 to 70.4). The results indicate that 18 F FDG-PET and PET/CT are relatively high sensitive and specific for the diagnosis of urinary bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25809703     DOI: 10.1007/s13277-014-2361-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

1.  Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods.

Authors:  E C Vamvakas
Journal:  Arch Pathol Lab Med       Date:  1998-08       Impact factor: 5.534

2.  Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.

Authors:  Andrea B Apolo; Jamie Riches; Heiko Schöder; Oguz Akin; Alisa Trout; Matthew I Milowsky; Dean F Bajorin
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

Review 3.  PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature.

Authors:  Koen Mertens; Dominique Slaets; Bieke Lambert; Marjan Acou; Filip De Vos; Ingeborg Goethals
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-11       Impact factor: 9.236

4.  Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations.

Authors:  L E Moses; D Shapiro; B Littenberg
Journal:  Stat Med       Date:  1993-07-30       Impact factor: 2.373

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.

Authors:  Gerald Antoch; Nina Saoudi; Hilmar Kuehl; Gerlinde Dahmen; Stefan P Mueller; Thomas Beyer; Andreas Bockisch; Jörg F Debatin; Lutz S Freudenberg
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

Review 7.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  BMJ       Date:  2003-01-04

8.  FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.

Authors:  Greet Swinnen; Alex Maes; Hans Pottel; Alain Vanneste; Ignace Billiet; Karl Lesage; Patrick Werbrouck
Journal:  Eur Urol       Date:  2009-05-18       Impact factor: 20.096

Review 9.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

10.  Conducting systematic reviews of diagnostic studies: didactic guidelines.

Authors:  Walter L Devillé; Frank Buntinx; Lex M Bouter; Victor M Montori; Henrica C W de Vet; Danielle A W M van der Windt; P Dick Bezemer
Journal:  BMC Med Res Methodol       Date:  2002-07-03       Impact factor: 4.615

View more
  5 in total

1.  Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma.

Authors:  Scott P Campbell; Alexander S Baras; Mark W Ball; Max Kates; Noah M Hahn; Trinity J Bivalacqua; Michael H Johnson; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal:  Ann Nucl Med       Date:  2017-10-24       Impact factor: 2.668

Review 2.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432

Review 3.  Role of PET/CT in muscle-invasive bladder cancer.

Authors:  Seok-Ki Kim
Journal:  Transl Androl Urol       Date:  2020-12

Review 4.  The Role of Lymph Node Dissection in the Treatment of Bladder Cancer.

Authors:  Francesco Cattaneo; Giovanni Motterle; Filiberto Zattoni; Alessandro Morlacco; Fabrizio Dal Moro
Journal:  Front Surg       Date:  2018-10-05

5.  Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma.

Authors:  Vera Wenter; Alexander Kretschmer; Lena M Unterrainer; Simon Lindner; Lennert Eismann; Jozefina Casuscelli; Franz-Josef Gildehaus; Vinh Ngoc Bui; Nathalie L Albert; Adrien Holzgreve; Leonie Beyer; Andrei Todica; Matthias Brendel; Clemens C Cyran; Alexander Karl; Christian G Stief; Stephan T Ledderose; Marcus Unterrainer; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-24       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.